Compared protective effect of nasal immunoprophylaxis using a new human monoclonal IgM antibody, human polyclonal antibodies, F(ab′)2, amantadine, and zanamivir for prophylaxis of influenza A virus pneumonia in mice

Military Medicine

Volumn 168, Issue 3, 2003, Pages 246-251

  Ramisse, Françoise ^a   Lhonneux, Anne ^b   Noury, Jacques ^b   Bazin, Hervé ^b   Cavallo, Jean Didier ^c   Hernandez, Eric ^c  

^a CENTRE D ETUDES DU BOUCHET   (France)

^b Laboratoires Technopharm   (France)

^c SERVICE D ENDOCRINOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY 3D2; MONOCLONAL ANTIBODY FAL11 2C3; MONOCLONAL ANTIBODY FAL8 1G4; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; ZANAMIVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNOPROPHYLAXIS; INFLUENZA VIRUS A; MOUSE; NONHUMAN; VIRUS PNEUMONIA;

EID: 0037341970     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.1093/milmed/168.3.246     Document Type: Article

References (22)

1. Kaiser L, Hayden FG: Hospitalizing influenza in adults. Curr Clin Top Infect Dis 1999; 19: 112-34.
2. Laurel VL, De Witt CC, Geddie YA, et al: An outbreak of influenza a caused by imported virus in the United States. July 1999. Clin Infect Dis 2001; 32: 1639-42.
3. Saito H, Takenaka H, Yoshida S, et al: Prevention from naturally acquired viral respiratory infection by interferon nasal spray. Rhinology 1985; 23: 291-5.
4. Wilson SZ, Knight V, Wyde PR, Drake S, and Couch RB: Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob Agents Chemother 1980; 17: 642-8.
5. Barnett JM, Cadman A, Burrell FM, et al: In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. Virology 1999; 265: 286-95.
6. 2 fragments. Clin Exp Immunol 1998; 111: 583-7.
7. Bazin H: Production of rat monoclonal antibodies with the LOU rat nonsecreting IR983F myeloma cell line. In: Protides of the Biological Fluids, pp 615-18. Edited by Peeters H. Oxford, Pergamon, 1982.
8. Gubareva LV, McCullers JA, Bethell RC, Webster RG: Characterization of influenza A/Hong Kong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. J Infect Dis 1998; 178: 1592-6.
9. Fenton RJ, Morley PJ, Owens IJ, et al: Chemoprophylaxis of influenza A virus infections with single doses of zanamivir demonstrates that zanamivir is cleared slowly from the respiratory tract. Antimicrob Agents Chemother 1999; 43: 2642-7.
10. Hayden FG: Prevention and treatment of influenza in immunocompromised patients. Am J Med 1997; 102: 55-60.
11. Kaiser L, Keene ON, Hammond JM, Elliott M, Hayden FG: Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med 2000; 160: 3234-40.
12. Kaiser L, Henry D, Flack NP, Keene O, Hayden FG: Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Clin Infect Dis 2000; 30: 587-9.
13. Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr., Elliott MJ, Crisp A: Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999; 282: 31-5.
14. Demicheli V, Jefferson T, Rivetti D, Deeks J: Prevention and early treatment of influenza in healthy adults. Vaccine 2000; 18: 957-1030.
15. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR: Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 1990; 64: 1375-7.
16. Tamura S, Funato H, Hirabayashi Y, et al: Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules. Eur J Immunol 1991; 21: 1337-44.
17. Houck P, Hemphill M, LaCroix S, Hirsh D, Cox N: Amantadine-resistant influenza A in nursing homes: identification of a resistant virus prior to drug use. Arch Intern Med 1995; 155: 533-7.
18. Mazanec MB, Lamm ME, Lyn D, Portner A, Nedrud JG: Comparison of IgA versus IgG monoclonal antibodies for passive immunization of the murine respiratory tract. Virus Res 1992; 23: 1-12.
19. Mozdzanowska K, Furchner M, Washko G, Mozdzanowski J, Gerhard W: A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J Virol 1997; 71: 4347-55.
20. Mozdzanowska K, Maiese K, Furchner M, Gerhard W: Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 1999; 254: 138-46.
21. Virelizier JL: Host defenses against influenza virus: the role of anti-hemagglutinin antibody. J Immunol 1975; 115: 434-9.
22. Okuno Y, Matsumoto KI, Isegawa Y, Ueda S: Protection against the mouse adapted A/FM/1/47 strain ofinfluenza A virus in mice by a monoclonal antibody with cross neutralizing activity among H1 and H2 strains. J Virol 1994; 68: 517-20.